Health
Pfizer and BioNTech to supply 30M doses of BNT162 vaccine candidate in UK – Seeking Alpha
Pfizer (NYSE:PFE) and collaboration partner BioNTech (NASDAQ:BNTX) announce an agreement with the UK to supply 30M doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2.Financial details were not disclosed.The companies are on track to begin a…
Pfizer (NYSE:PFE) and collaboration partner BioNTech (NASDAQ:BNTX) announce an agreement with the UK to supply 30M doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2.
Financial details were not disclosed.
The companies are on track to begin an anticipated Phase 2b/3 safety and efficacy trial later this month, seek regulatory review as early as October 2020 and manufacture globally up to 100M doses by the end of 2020 and more than 1.3B doses by end of 2021….
Continue Reading